Curaleaf’s initial agreement with Four 20 Pharma in 2022 acquired a 55% stake, with the remaining 45% completed in April 2026.
Ultimately, the full acquisition strengthens Curaleaf’s vertically integrated supply chain, stretching from cultivation in Portugal and Canada to global licensed distribution, such as in Germany.
The integration delivers a true seed-to-patient quality guarantee and full oversight at every stage. Since 2022, Curaleaf and Four 20 Pharma have collaborated closely to expand patient access, advance research initiatives, and streamline the international medical cannabis supply chain, validating a data-driven approach to research, education, cultivation, and product development.
Boris Jordan, CEO and Chairman, Curaleaf commented, “Completing this buyout of the remaining stake in Four 20 Pharma reinforces our commitment to Europe and underscores the strategic importance of building high-quality, locally anchored operations in a market that will continue to grow exponentially.”
Building on Four 20 Pharma’s success in Germany, Curaleaf has already launched the Four 20 brand in the United Kingdom and Poland and intends to continue expanding the brand across additional international markets, distributing high quality and compliant products.
Torsten Greif, Founder and Managing Director, Four 20 Pharma commented, “We built this company on an uncompromising commitment to quality, compliance, and patient care – values that align perfectly with Curaleaf’s international mission.”
We would also like to share that Torsten Greif has been appointed to the Curaleaf Board of Directors. With deep expertise in cannabis cultivation, regulatory strategy, and brand development, he has been instrumental in positioning Four 20 Pharma as a leading premium cannabis provider in Germany’s emerging medical cannabis market. Under his leadership, the company achieved a majority stake sale to Curaleaf, underscoring his strategic vision, cross-industry approach, and ability to find success in the evolving German cannabis market.
The appointment reinforces Curaleaf’s commitment to strategic leadership and operational excellence as the Company further integrates its European footprint and prepares for long-term growth across regulated markets.
